Early detection of prostate cancer with low PSA cut‐off values leads to significant stage migration in radical prostatectomy specimens
- 24 September 2003
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 57 (2) , 93-98
- https://doi.org/10.1002/pros.10278
Abstract
BACKGROUND The introduction of prostate-specific antigen (PSA) contributed to a shift in tumor stage at diagnosis in patients with prostate cancer. The aim of the present study was to evaluate the effects of PSA screening with low PSA cut-off values on mean total and percent-free PSA levels in patients with prostate cancers at the time of diagnosis as well as on pathologic stage and mean Gleason scores in positive biopsies and radical prostatectomy specimens. METHODS Data of 875 patients who were diagnosed with prostate cancers between 1996 and 2001 were analyzed. Patients were stratified into six groups according to the year of biopsy. Annual changes in total and percent-free PSA values, in Gleason scores of biopsies and radical prostatectomy specimens, and in pathologic stages of radical prostatectomy specimens were assessed. RESULTS Mean PSA of patients diagnosed with prostate cancer decreased from 13.11 ng/ml (percent-free PSA: 11.89%) in 1996 to 7.33 ng/ml (percent-free PSA: 12.58%) in 2001 (P < 0.05). The percentage of organ-confined prostatectomy specimens increased from 64.3% in 1996 to 81.5% in 2001 (P < 0.05). However, mean Gleason scores increased from 5.23 to 6.33 over the 6 years (P < 0.05). The percentage of patients with biopsy-proven prostate cancers and PSA values below 4 ng/ml increased from 14.0% in 1996 to 39.2% in 2001. In the group with PSA values below 4 ng/ml organ-confined cancers were found in 80.0–95.2% of patients. CONCLUSIONS PSAg screening with low cut-off levels has led to a significant reduction of mean baseline PSA levels in prostate cancer patients and to a significant increase in the percentage of organ-confined radical prostatectomy specimens, whereas mean Gleason scores have remained relatively constant. Prostate 57: 93–98, 2003.Keywords
This publication has 49 references indexed in Scilit:
- Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communitiesThe Prostate, 2002
- Impact of preoperative serum PSA level from 0 to 10 ng/ml on pathological findings and disease-free survival after radical prostatectomyThe Prostate, 2001
- Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancerThe Prostate, 2000
- RETRACTED: Prostate cancer screening in the Tyrol, Austria: experience and resultsEuropean Journal Of Cancer, 2000
- Improvement of specificity in PSA-based screening by using PSA-transition zone density and percent free PSA in addition to total PSA levelsThe Prostate, 1998
- THE USE OF PERCENT FREE PROSTATE SPECIFIC ANTIGEN FOR STAGING CLINICALLY LOCALIZED PROSTATE CANCERJournal of Urology, 1998
- CHARACTERISTICS OF SCREENING DETECTED PROSTATE CANCER IN MEN 50 TO 66 YEARS OLD WITH 3 TO 4 NG./ML. PROSTATE SPECIFIC ANTIGENJournal of Urology, 1998
- The early detection of prostate carcinoma with prostate specific antigenCancer, 1997
- The Free-to-Total Serum Prostate Specific Antigen Ratio for Staging Prostate CarcinomaJournal of Urology, 1997
- Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate CancerNew England Journal of Medicine, 1991